CP-316,311

CP-316,311 is a potent and selective small molecule antagonist of the corticotropin-releasing factor receptor 1 (CRF1), also known as corticotropin-releasing hormone receptor type 1. It was developed by Pfizer for the treatment of anxiety disorders and major depressive disorder. The drug acts by inhibiting CRF1 receptors with high affinity (IC50 ≈ 6.8 nM), thereby blocking the effects of endogenous and exogenous corticotropin-releasing factor in the central nervous system. Despite demonstrating safety and tolerability in clinical trials, it failed to show efficacy in treating major depression or anxiety disorders and its development was discontinued after phase II trials[1][2][3][8].

Other names

Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-compound 2 [PMID: 18260619]